Last $27.50 USD
Change Today -0.09 / -0.33%
Volume 20.5K
SAGE On Other Exchanges
Symbol
Exchange
NASDAQ GM
OTC US
As of 10:15 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

sage therapeutics inc (SAGE) Snapshot

Open
$27.77
Previous Close
$27.59
Day High
$27.77
Day Low
$26.67
52 Week High
07/22/14 - $30.75
52 Week Low
07/18/14 - $26.10
Market Cap
707.1M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
25.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SAGE THERAPEUTICS INC (SAGE)

Related News

No related news articles were found.

sage therapeutics inc (SAGE) Related Businessweek News

No Related Businessweek News Found

sage therapeutics inc (SAGE) Details

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat rare central nervous system disorders. The company’s lead product candidate includes SAGE-547, an intravenous (IV) agent that is in Phase I/II clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). Its products in IND-enabling toxicology and safety pharmacology testing comprise SAGE-689, an adjunctive second-line therapy for the treatment of status epilepticus (SE); and SAGE-217, an IV monotherapy for the treatment of refractory status epilepticus, as well as an orally delivered maintenance therapeutic to prevent recurrent seizures in patients whose SE, RSE, or SRSE has resolved. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.

21 Employees
Last Reported Date: 07/18/14
Founded in 2011

sage therapeutics inc (SAGE) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $153.0K
Chief Medical Officer
Total Annual Compensation: $149.0K
Chief Scientific Officer
Total Annual Compensation: $302.5K
Compensation as of Fiscal Year 2013.

sage therapeutics inc (SAGE) Key Developments

SAGE Therapeutics Receives Fast Track Designation for Lead Compound SAGE-547 to Treat Status Epilepticus

SAGE Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the SAGE-547 development program. SAGE-547 is an allosteric modulator of GABA(A) receptors in development for the treatment of adult patients with refractory status epilepticus who have not responded to standard regimens (super-refractory status epilepticus, or SRSE). SAGE is currently evaluating SAGE-547 in a Phase 1/2 clinical trial for the treatment of SRSE. Preliminary data indicate that the first four patients enrolled in the clinical trial met the key efficacy endpoint, in that each was successfully weaned off his or her anesthetic agent while SAGE-547 was being administered. There have also been no reported drug-related serious adverse events in these four patients to date. The fast track designation for SAGE-547 recognizes the significant unmet need that exists in the treatment of super-refractory status epilepticus. Fast track designation is granted by the FDA to facilitate the development and expedite the review of drug candidates that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABA(A) receptors. GABA(A) receptors are widely regarded as validated drug targets for a variety of CNS disorders, with decades of research and multiple approved drugs targeting these receptor systems. SAGE-547 is an intravenous agent in Phase 1/2 clinical development as an adjunctive therapy, a therapy combined with current therapeutic approaches, for the treatment of SRSE.

Sage Therapeutics, Inc.(NasdaqGM:SAGE) added to NASDAQ Composite Index

Sage Therapeutics, Inc. will be added to the NASDAQ Composite Index.

SAGE Therapeutics Appoints James M. Frates as Board of Directors

SAGE Therapeutics announced the appointment of James M. Frates to the company's board of directors. Mr. Frates currently serves as senior vice president and chief financial officer at Alkermes.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAGE:US $27.50 USD -0.09

SAGE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SAGE.
View Industry Companies
 

Industry Analysis

SAGE

Industry Average

Valuation SAGE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 11.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGE THERAPEUTICS INC, please visit www.sagerx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.